




PHARMACEUTICAL 2021

Propanc Biopharma Inc.
Rank 397 of 402





PHARMACEUTICAL 2021

Propanc Biopharma Inc.
Rank 397 of 402

The relative strengths and weaknesses of Propanc Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Propanc Biopharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 601% points. The greatest weakness of Propanc Biopharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 404% points.

The company's Economic Capital Ratio, given in the ranking table, is -568%, being 616% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	69
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,740
Liabilities, Non-Current	0
Other Assets	24
Other Compr. Net Income	201
Other Expenses	-102
Other Liabilities	0
Other Net Income	-1,381
Other Revenues	0
Property and Equipment	5.7
Research and Development	180
Selling, General and Administrative Expense	3,281

Output Variable	Value in 1000 USD
Assets	99
Liabilities	3,740
Expenses	3,360
Revenues	0
Stockholders Equity	-3,641
Net Income	-4,741
Comprehensive Net Income	-4,640
Economic Capital Ratio	-568%